FinancingRegulatory filing
What was reported
On September 4, 2026 (the “Closing Date”), Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into a Credit Agreement (the “Credit Agreement”) with the lenders from time to time party thereto (“Lenders”), and OrbiMed Royalty & Credit Opportunities V, LP, as administrative agent (“Administrative Agent”). OrbiMed Royalty & Credit Opportunities IV, LP, and OrbiMed Royalty & Credit Opportunities V, LP, are the initial Lenders.U.S. Securities and Exchange Commission (EDGAR) · 8-K: 8-K · Sep 4, 2026 · Open the source ↗
What the evidence supports
Intellia Therapeutics told the SEC (Form 8-K, Item 1.01) that it entered into a financing arrangement or sold its securities. The filing gives Sep 4, 2026 as the date of the earliest event reported.
What remains unknown
How much money will actually be raised or drawn, at what final price, and how it will be used beyond what the company stated. Stated amounts can be maximums or targets rather than money already received.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Form 8-K, Item 1.01 textOn September 4, 2026 (the “Closing Date”), Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into a Credit Agreement (the “Credit Agreement”) with the lenders from time to time party thereto (“Lenders”), and OrbiMed Royalty & Credit Opportunities V, LP, as administrative agent (“Administrative Agent”). OrbiMed Royalty & Credit Opportunities IV, LP, and OrbiMed Royalty & Credit Opportunities V, LP, are the initial Lenders.U.S. Securities and Exchange Commission (EDGAR) · 8-K: 8-K · Sep 4, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:54 UTC
Intellia Therapeutics reports entry into a material definitive agreement (Form 8-K, Item 1.01)
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.